STERIS(US:STE)2020-09-17 12:34Financial Performance Highlights - 4Q20 net sales were $233.4 million, a decrease of 2.5% compared to 4Q19[7] - FY20 net sales were $1016.0 million, an increase of 10.7% compared to FY19[11] - 4Q20 GAAP EPS was $(0.05), compared to $0.21 in 4Q19[9] - FY20 GAAP EPS was $0.40, compared to $1.32 in FY19[12] - 4Q20 Non-GAAP EPS was $0.24, compared to $0.63 in 4Q19[9] - FY20 Non-GAAP EPS was $1.65, compared to $2.37 in FY19[12] Segment Performance (FY20) - Medical segment net sales were $468.1 million, a decrease of 10.6%[40] - Life Sciences segment net sales were $195.4 million, an increase of 0.2%[43] - Dental segment net sales were $322.4 million, an increase of 92.3%[46] - Dialysis segment net sales were $30.2 million, a decrease of 5.3%[49] Balance Sheet and Debt - Cash and cash equivalents totaled $277.9 million as of July 31, 2020[28] - Net debt was $835.5 million as of July 31, 2020[35] - Net debt to adjusted EBITDAS was 4.7x[37]